Recently, ACE USA has taken a step to expand its web-based desktop portal, ACE Worldview. We expect the extension of the technology to ARM business to help the company augment its primary casualty line of business, thereby strengthening its competitive position in the market.
Earlier, ACE USA introduced new services through its risk management services company, ESIS Inc. pertaining to the healthcare industry construction projects. This launch was an augmentation to the company�� Contractors Pollution Liability (CPL) coverage named Owner-Controlled Insurance Program (OCIP) launched in Jun 2013.
Last month, ACE Limited formed a new specialty casualty division within its excess and surplus lines insurance company, ACE Westchester. The formation of the new division is aimed at expanding the Specialty Casualty business of ACE Limited in the U.S. The division will cater to industries like construction, auto and railroad transportation, energy and public entities.
Top 10 Diversified Bank Companies To Invest In Right Now: Oxygen Biotherapeutics Inc.(OXBT)
Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body in the United States. The company primarily offers Oxycyte, a perfluorcarbon (PFC) based oil in water emulsion that carries oxygen and is been formulated for intravenous delivery for the treatment of traumatic brain injury, spinal cord injury, and decompression sickness; and other PFC-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. It also provides Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It markets its Dermacyte line of products through buydermacyte.com; and to dermatologists and medical spas with a combination of in-house sales, independent sales agents, and distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its n ame to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is based in Morrisville, North Carolina.
Advisors' Opinion:- [By John Udovich]
Yesterday, small cap Oxygen Biotherapeutics, Inc (NASDAQ: OXBT) surged 87.33% to $2.81 after published results showed that its levosimendan was associated with reduced mortality, meaning its probably time to do a reality check about the stock as well as look at its performance against that of industry benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By Bryan Murphy]
To say that Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) has made its presence known over the past three weeks would be an understatement. It would be more accurate and fairer to say OXBT been an "in your face" kind of name that you couldn't look past even if you wanted to. Rather than continue to sidestep it, care to stop, invest two minutes of time, and get the Q&D version of what's really going on here? If so, read on.
- [By Lauren Pollock]
Oxygen Biotherapeutics Inc.(OXBT) said it agreed to buy about $4.8 million in assets from Phyxius Pharma that treat cardiac-surgery patients. Shares of Oxygen Biotherapeutics rose.
- [By Paul Ausick]
Stocks on the Move: GT Advanced Technologies Inc. (NASDAQ: GTAT) is up 20.5% at $10.10 after earnings and signing deal to supply Apple Inc. (NASDAQ: AAPL) with sapphire glass. Marvell Technology Group Ltd. (NASDAQ: MRVL) is up 8.5% at $13.03 following reports of an investment by KKR & Co. (NYSE: KKR). Oxygen Biotherapeutics Inc. (NASDAQ: OXBT) is up 62.7% at $8.38 along with other biotech stocks making big moves today.
10 Best Railroad Stocks To Buy For 2014: M/I Homes Inc. (MHO)
M/I Homes, Inc., together with its subsidiaries, primarily operates as a builder of single-family homes in the United States. The company operates in two segments, Homebuilding and Financial Services. The Homebuilding segment designs, constructs, markets, and sells single-family homes, attached townhomes, and condominiums to first-time, move-up, empty-nester, and luxury buyers in the Midwest, Mid-Atlantic, and southern regions. It markets its finished homes through company-employed sales consultants under the M/I Homes, Showcase Homes, and TriStone Homes trade names. This segment also purchases undeveloped land to develop into finished lots for the construction of single-family homes and for sale to others. As of December 31, 2011, it had 3,041 developed lots and 625 lots under development in inventory, as well as owned raw land expected to be developed into approximately 3,491 lots. The Financial Services segment is involved in originating and selling mortgages, and colle cting fees for title insurance and closing services. This segment serves as a title insurance agent by providing title insurance policies, and examination and closing services to purchasers of its homes. M/I Homes, Inc. was founded in 1973 and is based in Columbus, Ohio.
Advisors' Opinion:- [By James E. Brumley]
Given the bad news regarding new-home sales unveiled� this morning, it's no real surprise that homebuilder stocks like KB Home (NYSE:KBH) and M/I Homes Inc. (NYSE:MHO) are struggling. KBH is down 2.8% as of the last look, while MHO shares are off 4.1%. None of the major homebuilder names are underwater as much as Meritage Homes Corp. (NYSE:MTH) is today, though, with its 8.6% drubbing. Already struggling, today's stumble from MTH may well jump-start a more serious selloff that the bulls have thus far been able to stave off.
- [By Travis Hoium]
What: Shares of M/I Homes (NYSE: MHO ) fell as much as 10% today after the company released earnings.
So what: Revenue jumped 37%, to $234.6 million, in the second quarter, and net income nearly doubled, to $6.05 million, or $0.25 per share. But analysts were expecting $258 million in revenue, and earnings of $0.36 per share, so results were still behind estimates.�
- [By George Putnam, Editor, New Generation Research, Inc.]
Steve Halpern: You have an exception to that rule, you look at a smaller home builder, M/I Homes (MHO), and you like that. Could you tell us why.
- [By The Oxen Group]
According to home construction news site Builderonline.com, MDC ranks 11th in terms of total number of home closings for the year 2012. Out of the top 10 competitors, MDC has the lowest PEG value, followed by Ryland Group (RYL) and Meritage Homes (MTH) with 0.23 and 0.6, respectively. The current pe ratio is lowest for the company followed by Ryland Group with 7.4 and Meritage Homes (MHO) with 11. In terms of forward pe, the top ten competitors have values in the 10-14 range. Putting numbers in perspective, relative to its competitors we believe that MDC presents a better value for investors looking to take advantage of the real estate market rebound.
10 Best Railroad Stocks To Buy For 2014: Mobile Mini Inc.(MINI)
Mobile Mini, Inc. provides portable storage solutions in North America, the United Kingdom, and the Netherlands. It offers a range of portable storage products in varying lengths and widths with various features, such as its patented locking systems, premium doors, and electrical wiring and shelving. The company?s products include remanufactured and modified steel storage containers, steel security office/storage combination and security office units, wood mobile office units, and steel records storage containers, as well as non-core storage units consisting of van trailers and other manufactured storage products. Mobile Mini also provides its products on lease basis to its customers. Its customers use its products for a range of storage applications, including retail and manufacturing supplies, inventory and maintenance supplies, temporary offices, construction materials and equipment, documents and records, and household goods. The company serves large and small retaile rs, construction companies, medical centers, schools, utilities, manufacturers and distributors, the United States and the United Kingdom military, government agencies, hotels, restaurants, entertainment complexes, and households. As of December 31, 2011, it operated a lease fleet of approximately 237,600 portable storage units through 109 branches in the United States, 4 branches in Canada, 19 branches in the United Kingdom, and 1 branch in the Netherlands. The company was founded in 1983 and is headquartered in Tempe, Arizona.
Advisors' Opinion:- [By Brian Pacampara]
What: Shares of portable storage specialist Mobile Mini (NASDAQ: MINI ) climbed 10% today after its quarterly results topped Wall Street expectations.
10 Best Railroad Stocks To Buy For 2014: Mylan Inc (MYL)
Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.
As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).
Generics Segment
The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.
In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.
In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.
Specialty Segment
The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.
Advisors' Opinion:- [By Ben Eisen]
Mylan Inc. (MYL) �gained 3.6% after the pharmaceuticals company said it had settled litigation with Teva Pharmaceutical Industries (TEVA) over its Copaxone product.
10 Best Railroad Stocks To Buy For 2014: Tree.com Inc.(TREE)
Tree.Com, Inc., through its subsidiaries, engages in lending business in the United States. It owns various brands and businesses that provide information, tools, advice, products, and services for consumers looking to comparison shop for loans, real estate, and other services from businesses and professionals. The company?s LendingTree Loans segment originates, processes, approves, and funds various types of residential real estate loans primarily under the LendingTree Loans brand name. It offers a range of adjustable and fixed rate mortgage loans, including conforming and prime loans, as well as non-conforming and FHA loans. This segment sources its leads through online and telephone services, as well as through various non-LendingTree channels, such as third-party online lead aggregators and direct mail marketing campaigns. Its Exchanges segment consists of online lead generation networks under the LendingTree.com, GetSmart.com, DegreeTree.com, HealthTree.com, LendingT reeAutos.com, DoneRight.com, and InsuranceTree.com brands; and call centers that connect consumers and service providers, principally in the lending, higher education, home services, insurance, and automobile marketplaces. This segment also provides unsecured loans, automobile loans, credit cards, and various consumer insurance products, as well as opportunities for students seeking institutions of higher education, and home improvement professional services with contractors. The company is based in Charlotte, North Carolina.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Casper1774 Studio/Shutterstock You may not have noticed it, but recently, it's gotten easier to buy a new home. Last year, a strong housing market combined with fears that the Federal Reserve would eventually begin tapering its purchases of mortgage bonds. Together, these factors helped drive up the cost of a 30-year fixed-rate mortgage from about 3.3 percent in January 2013 to nearly 4.6 percent by September. Since then, mortgage rates have backed off those recent highs, bobbling back and forth between 4.5 percent or so, and, recently, 4.2 percent. This has helped to keep housing affordable for those who want to buy a home. But it did pose the bankers a dilemma: How could they get more people to want to buy homes in the first place, so that they could sell more mortgages? Answer: Make it easier to apply for a mortgage. Mortgage Down Payments Live Down to Their Name Last spring, lending data website LendingTree.com (TREE) released a report showing that the average down payment demanded by mortgage bankers to obtain a 30-year fixed-rate mortgage had fallen 9.4 percent since mid-2011. At 16.1 percent, it was nearly 4 full percentage points shy of the old rule of thumb that a home buyer should put 20 percent down on a new home. Six months later, average down payments had fallen to 15.73 percent of the value of a home. Now, LendingTree has put out an updated report showing that after down payment demands inched back up in 2013 (to 16.01 percent), they've begun to fall once more. At last report, mortgage bankers on average want to see a 15.78 percent down payment -- a bit more than what we saw last fall, but still continuing the downward trend in down payments. Why? One clue may be found in recent comments from Freddie Mac vice president and chief economist Frank Nothaft, who's been highlighting declines in existing-home sales, in new-home sales as well, and even in permits taken out to build houses, in a series of reports through April. If home-buying is
- [By Jake L'Ecuyer]
Meanwhile, top decliners in the sector included Tree.Com (NASDAQ: TREE), down 4.7 percent, and Hilltop Holdings (NYSE: HTH), off 6.7 percent.
Top Headline
Office Depot (NYSE: ODP) reported upbeat first-quarter results and announced its plans to close at least 400 stores in the United States. For the full year, Office Depot also lifted its adjusted operating income outlook to at least $160 million versus $140 million. Office Depot posted a quarterly net loss of $109 million, or $0.21 per share, versus a year-ago loss of $17 million, or $0.06 per share.
10 Best Railroad Stocks To Buy For 2014: BG Medicine Inc.(BGMD)
BG Medicine, Inc., a life sciences company, engages in the discovery, development, and commercialization of diagnostic tests based on biomarkers in the United States. Its product pipeline includes BGM Galectin-3, a diagnostic test for heart failure that measures galectin-3 levels in blood plasma or serum; AMIPredict, a multivariate biomarker blood-based test for atherothrombotic cardiovascular disease; and LipidDx, a blood-based protein assay for the management of patients with lipid disorders. The company also offers TNF alpha blockers comprising Enbrel, Remicade and Humira, which are treatments indicated for autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn?s disease. It has strategic collaborations and initiatives with pharmaceutical companies and other healthcare organizations, including Abbott Laboratories; ACS Biomarker B.V.; Humana Inc.; Merck & Co., Inc.; and Laboratory Corporation of America. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.
Advisors' Opinion:- [By James E. Brumley]
What do BG Medicine, Inc. (NASDAQ:BGMD) and Pentair, Ltd. (NYSE:PNR) have in common? Most investors would say absolutely nothing. BGMD is a small cap medical diagnostics company, while PNR is a large cap industrial equipment manufacturer. Those are worlds that simply never collide. The directions each stock has been traveling in over the past few months have even been polar opposites.
- [By Roberto Pedone]
Another stock that's starting to move within range of triggering a big breakout trade is BG Medicine (BGMD), which develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the U.S. This stock has been pushed lower by the sellers over the last three months, with shares down sharply by 20%.
If you take a glance at the chart for BG Medicine, you'll notice that this stock has been uptrending a bit for the last month, with shares moving higher from its low of 90 cents per share to its recent high of $1.12 a share. During that uptrend, shares of BGMD have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of BGMD within range of triggering a big breakout trade above some key near-term overhead resistance levels.
Traders should now look for long-biased trades in BGMD if it manages to break out above some near-term overhead resistance levels at $1.08 to $1.12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.56 million shares. If that breakout gets started soon, then BGMD will set up to re-fill some of its previous gap-down-day zone from May that started near $1.30 a share. Any high-volume move above $1.30 will then give BGMD a chance to tag its next major overhead resistance levels at $1.50 to around $1.70 a share.
Traders can look to buy BGMD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at 96 cents to 90 cents per share. One can also buy BGMD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
10 Best Railroad Stocks To Buy For 2014: Alliance One International Inc (AOI)
Alliance One International, Inc., incorporated on October 19, 1994, is a leaf tobacco merchant. The Company is engaged in purchasing, processing, packing, storing and shipping tobacco to manufacturers of cigarettes and other consumer tobacco products globally. The Company deals primarily in flue-cured, burley, and oriental tobaccos that is used in international brand cigarettes. The Company�� revenues are primarily comprised of sales of processed tobacco and fees charged for processing and related services to these manufacturers of tobacco products. The Company does not manufacture cigarettes or other consumer tobacco products.
Tobacco is primarily purchased directly from suppliers with small quantities still sold at auction. In non-auction markets, the Company purchases tobacco directly from suppliers and the Company assumes the risk of matching the quantities and grades required by its customers to the entire crop it must purchase under contract. The Company purchases tobacco in more than 35 countries. During the year ended March 31, 2013 (fiscal 2013), approximately 30% of the Company�� purchases of tobacco were from the South America operating segment, approximately 5% were from the Value Added Services operating segment and approximately 65% from the Other Regions operating segment.
The Company processes tobacco to meet each customer's specifications as to quality, yield, chemistry, particle size, moisture content and other characteristics. Unprocessed tobacco is a semi-perishable commodity that generally must be processed within a relatively short period of time to prevent fermentation or deterioration in quality. The Company processes tobacco in more than 35 owned and third-party facilities around the world including Argentina, Brazil, China, Zimbabwe, Jordan, Guatemala, India, Tanzania, the United States, Malawi, Thailand, Germany, Indonesia, Macedonia, Bulgaria and Turkey. These facilities encompass all export locations of flue-cured, burley and oriental tobaccos! . In addition, the Company has entered into contracts, joint ventures and other arrangements for the purchase of tobacco grown in substantially all other countries that produce export-quality flue-cured and burley tobacco. The Company also sells a small amount of processed but unthreshed flue-cured and burley tobacco in loose-leaf and bundle form to certain customers. In 2013, Alliance One delivered approximately 41% of its tobacco sales to customers in Europe and approximately 19% to customers in the United States. In 2013, these Belgium sales accounted for 20% of sales to customers in Europe. The Company ships tobacco to manufacturers of cigarettes and other consumer tobacco products located in approximately 90 countries around the world as designated by these manufacturers.
The Company competes with Japan Tobacco, Inc. (JTI), Philip Morris International, Inc. (PMI), and Imperial Tobacco Group PLC.
Advisors' Opinion:- [By John Emerson]
Camtek was an automated optical inspection (AOI) company that designed and manufactured inspection systems for printed circuit boards (PCB). Further, they were in the process of designing systems to inspect semiconductors as well. The logic for investing in AOI companies was simple: Many circuit boards still employed visual inspection and circuits were getting smaller every year.
- [By Bryan Murphy]
It may seem trite (and a little dated) on the surface, but Warren Buffett's sage advice stands as tall today as it did the first time her ever said it.... "Be fearful when others are greedy, and be greedy when others are fearful." And, to say investors have been fearful of oil names like Kosmos Energy Ltd (NYSE:KOS), Africa Oil Corp. (CVE:AOI), and Hydrocarb Energy Corp. (OTCBB:HECC) of late would be an understatement. Not only have all three been pressured against a backdrop of plunging oil prices, HECC, KOS, and AOI have been doubly pressured because a big piece of what they do within their oil exploration exploits is done in Africa, where oil's recent volatility has been particularly disruptive. As Buffett� has accurately explained so many times in the past though, trends have a funny way of ending right around the time most investors are certain they'll never end.
- [By John Emerson]
As noted previously, I rode the elevator up and then back down on Camtek (CAMT), a tiny Israeli automated optical inspection (AOI) company. By late 2008 the company had fallen to below $1 per share. Both of Camtek�� larger rivals, RTEC and ORBK, had dropped to absurdly low levels by November 2008. I used the opportunity to switch out of CAMT and some of my other losing propositions in favor of these superior companies. In the process, I created a large amount of tax loss carry-forwards which would allow me to minimize my future taxation when I decided to sell these cyclical entities.
No comments:
Post a Comment